ANI Pharma says Phase 4 SYNCHRONICITY trial meets co-primary endpoints for ILUVIEN in chronic posterior uveitis
ANIP•ANI Pharmaceuticals said its Phase 4 SYNCHRONICITY trial of ILUVIEN met both co-primary endpoints, showing improved vision and reduced retinal swelling through 24 months. Most patients had no inflammation recurrence over two years.
1. Trial results
ANI Pharmaceuticals reported positive Phase 4 SYNCHRONICITY trial results for ILUVIEN in chronic non-infectious posterior segment uveitis. The trial met both co-primary endpoints, showing improved vision and reduced retinal swelling that held through 24 months; most patients had no inflammation recurrence over two years.
2. Safety and presentation
The safety profile matched prior experience, with eye-pressure increases and cataracts among the main treatment-related events. Six-month and two-year findings were presented as a late-breaking oral session at the American Academy of Ophthalmology 2026 meeting.
